Get the Stockscreener App
0.00
100.00%
-104.91
Exact Sciences Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$104.91
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$20.03B
Revenue:
$3.25B
Net Income/Loss:
$-207.95M
P/E Ratio:
0.00
EPS:
-1.1046
Net Cash Flow:
$356.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
576.41 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
569.54 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
242.94 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
140.54 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences stock trades steady as colorectal screening momentum meets earnings pressure - Ad-hoc-news.de
Exact Sciences stock advances on evidence from latest results - Ad-hoc-news.de
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Exact Sciences stock trades steadily as revenue grows and screening portfolio expands - Ad-hoc-news.de
At Home Cancer Testing Market Size & Growth Analysis, 2026-2035 - Market Business Insights
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Exact Sciences stock trades steady as revenue growth and screening demand support valuation - Ad-hoc-news.de
Exact Sciences stock trades near recent highs as screening demand supports revenue growth - Ad-hoc-news.de
Exact Sciences stock holds as investors await fresh numbers - AD HOC NEWS
Exact Sciences stock trades steadily as screening growth offsets guidance reset - Ad-hoc-news.de
Exact Sciences stock trades around recent range as screening revenue grows and losses narrow - Ad-hoc-news.de
Exact Sciences stock trades steady as Cologuard growth supports 2025 outlook - Ad-hoc-news.de
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Abbott raises 2026 profit forecast on strength in diagnostics, medical devices - Reuters
Abbott statement on cyber incident in Cancer Diagnostics business - Abbott
If You Invested $1,000 in Exact Sciences Corp (EXAS) - Stock Titan
Exact Sciences builds out cancer diagnostics. Operations and Nasdaq listing shape the story - ad-hoc-news.de
Exact Sciences Corp background and business model - ad-hoc-news.de
Exact Sciences stock leans on its screening base. Investors watch the U.S. testing franchise. - Ad-hoc-news.de
Exact Sciences focuses on cancer screening and long-term growth - Ad-hoc-news.de
Exact Sciences outlines long term diagnostics growth as cancer screening demand expands - ad-hoc-news.de
The Cologuard testExact Sciences leans on at-home colon cancer screening - Ad-hoc-news.de
Exact Sciences focuses on cancer diagnostics as investors track its long term growth prospects - ad-hoc-news.de
Exact Sciences Corp outlines growth ambitions as cancer screening demand expands - ad-hoc-news.de
Exact Sciences holds steady as investors await a fresh catalyst - AD HOC NEWS
Exact Sciences focuses on cancer diagnostics as investors weigh long-term growth - Ad-hoc-news.de
Exact Sciences highlights cancer screening focus as diagnostics portfolio expands - AD HOC NEWS
List of 29 Acquisitions by Abbott (Jul 2026) - Tracxn
Oncotype DX Breast Recurrence Score from Exact SciencesHow one test shapes US cancer care - AD HOC NEWS
Exact Sciences with steady analyst picture, shares trade on NASDAQ - Ad Hoc News
Exact Sciences opens the week with a clear earnings calendar, shares on NASDAQ in focus - ad-hoc-news.de
Cologuard from Exact Sciences Corp.multi-target stool DNA test reshapes home screening - Ad-hoc-news.de
Exact Sciences background and strategy, shares on NASDAQ in a diagnostics peer view - AD HOC NEWS
Exact Sciences consensus stays constructive, analysts see upside for the shares - AD HOC NEWS
Labcorp rolls out colorectal cancer screening test nationwide - MedTech Dive
Exact Sciences analyst focus on estimates, shares under Wall Street scrutiny - AD HOC NEWS
Align Technology Announces Board Leadership Transition: Kevin Conroy Named Chairman, Succeeding C. Raymond Larkin, Jr. in July 2026 - Minichart
Exact Sciences Corp (EXAS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exact Sciences StockAnalyst consensus and valuation snapshot - AD HOC NEWS
Why Cologuard from Exact Sciences is quietly changing at-home cancer screening - AD HOC NEWS
Align Taps Growth Architect Kevin Conroy as Chairman for Next Innovation Era - BriefGlance
Exact Sciences Corp (EXAS) Institutional Confidence - TradingKey
Exact Sciences Corp (EXAS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exact Sciences Corp (EXAS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exact Sciences Corp (EXAS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exact Sciences Corp (EXAS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exact Sciences Corp (EXAS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exact Sciences Corp (EXAS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exact Sciences Corp. Stock (US30063P1057): shares in focus amid quiet newsflow - AD HOC NEWS
Exact Sciences Corp. Stock (US30063P1057): Technical picture in focus after recent volatility - AD HOC NEWS
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):